Clark Capital Management Group Inc. Lowers Position in Novo Nordisk A/S (NYSE:NVO)

Clark Capital Management Group Inc. lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 39.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 315,892 shares of the company’s stock after selling 205,426 shares during the period. Clark Capital Management Group Inc.’s holdings in Novo Nordisk A/S were worth $27,173,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Diversified Trust Co increased its stake in Novo Nordisk A/S by 13.9% during the fourth quarter. Diversified Trust Co now owns 3,246 shares of the company’s stock worth $279,000 after acquiring an additional 395 shares during the last quarter. First Hawaiian Bank increased its position in Novo Nordisk A/S by 30.3% during the 4th quarter. First Hawaiian Bank now owns 22,259 shares of the company’s stock worth $1,915,000 after purchasing an additional 5,171 shares in the last quarter. ORG Partners LLC raised its holdings in Novo Nordisk A/S by 181.7% in the fourth quarter. ORG Partners LLC now owns 1,003 shares of the company’s stock valued at $86,000 after buying an additional 647 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in Novo Nordisk A/S by 0.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 290,489 shares of the company’s stock worth $24,988,000 after buying an additional 1,051 shares during the period. Finally, A. D. Beadell Investment Counsel Inc. increased its position in shares of Novo Nordisk A/S by 41.1% in the fourth quarter. A. D. Beadell Investment Counsel Inc. now owns 13,012 shares of the company’s stock worth $1,119,000 after acquiring an additional 3,787 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $64.78 on Friday. The firm has a fifty day moving average of $69.65 and a two-hundred day moving average of $86.58. The firm has a market cap of $290.72 billion, a P/E ratio of 19.69, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $79.17 billion. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on NVO shares. Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. BMO Capital Markets reissued a “market perform” rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.